# Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

> **NCT03190941** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 110 (estimated)

## Conditions studied

- Pancreatic Cancer
- Gastric Cancer
- Gastrointestinal Cancer
- Colon Cancer
- Rectal Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Anti-KRAS G12V mTCR PBL
- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT03190941
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-09-21
- **Primary completion:** 2027-06-29
- **Final completion:** 2028-06-29
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03190941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03190941, "Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03190941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*